Background
Methods
Results
N | Round 1 disagreement | Round 2 disagreement | |
---|---|---|---|
Overall | 735 | 40% | 6% |
Part I: Should a test of corneal sensitivity be performed? | 646 | 42% | 7% |
Scenarios that differed by degree of epithelial defect | |||
No epithelial changes (no staining) or defect | 256 | 38% | 1% |
Newly observed epithelial changes (staining) but no defect | 256 | 45% | 14% |
Newly observed defect | 128 | 46% | 3% |
Scenarios that differed by history of diabetes | |||
No diabetes or with well-controlled diabetes without evidence of end-organ damage | 320 | 32% | 3% |
Persistent poorly controlled diabetes and/or with evidence of end-organ damage | 320 | 53% | 10% |
Part II: Rate the adequacy tests to diagnose and stage neurotrophic keratopathy | 20 | 25% | 10% |
Part III: Rate the appropriateness various treatments | 69 | 20% | 3% |
Scenarios that differed by disease stage | |||
Stage 1 | 23 | 26% | 4% |
Stage 2 | 23 | 17% | 0% |
Stage 3 | 23 | 17% | 4% |
Scenarios that differed by treatment type | |||
Medical management | 27 | 22% | 0% |
Non-surgical intervention | 24 | 25% | 4% |
Surgical intervention | 15 | 13% | 7% |
Corneal sensitivity testing
Strongly recommended | May be considered |
---|---|
• Persistent epithelial defect that does not improve within 14 days • Painless, newly observed epithelial defect of unknown etiology • History of herpetic eye disease • History of procedures that might have damaged the trigeminal nerve or conditions that might have involved the trigeminal nerve • Pain in the affected eye and multiple, concurrent risk factors, such as persistent poorly controlled diabetes and either reduced blink or a history of corneal procedures | • Acquired limbal stem cell deficiency • Newly observed epithelial staining and persistent poorly controlled diabetes • Persistent poorly controlled diabetes and vision changes not ascribed to diabetic retinopathy or cataract (even in the absence of corneal findings) |
Tests for diagnosis and staging
Treatments
Early/less severe (e.g., Stage 1) | Moderate (e.g., Stage 2) | Later/more severe (e.g., Stage 3) | |
---|---|---|---|
Discontinue all preservative-containing topical medications | a | a | a |
Medical management | |||
Topical preservative-free drops | a | a | a |
Topical preservative-free gel drops or ointments | a | a | a |
Autologous serum drops, human umbilical cord serum, platelet rich plasma | a | a | a |
Recombinant human nerve growth factor (cenegermin) | b | a | a |
Prophylactic topical preservative-free antibiotics (excluding aminoglycosides) | a | a | |
Matrix metalloproteinases inhibitors | b | a | a |
Non-surgical intervention (i.e., office procedures) | |||
Corneal therapeutic contact lenses | b | a | b |
Fresh-frozen self-retained amniotic membrane | a | a | |
Punctal occlusion | a | a | a |
Synthetic (cyanoacrylate) tissue adhesive | a | ||
Surgical intervention (i.e., operating room procedures) | |||
Tarsorrhaphy | b | a | |
Amniotic membrane transplant | b | a | |
Corneal neurotization | b | a |